EXIDEINDNSEExide Industries Limited· Auto AncillariesMediumNeutral
Announced Mon, 11 May · 15:49 IST

Exide Industries Limited has informed the Exchange about Transcript of Earnings Call held on 6th May 2026.

Investor Communications View source PDF

EXIDEIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.2%1-day move
₹351.55
prior close
₹350.15
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.5+0.0-0.5+0.2-0.2-0.6-0.7-2.4-2.1-3.2+13.7+11.8+20.4
Up moveDown movePending
AI summary

Exide Industries reported its highest-ever quarterly revenue in Q4 FY26 with 9.4% YoY growth, driven by strong double-digit performance across 2-wheeler OEM, 4-wheeler OEM, home UPS, solar (crossing Rs. 1,000 crore for full year), and industrial infrastructure. Domestic business grew 12.5% YoY. However, commodity inflation created a net Rs. 150 crore material cost headwind, compressing gross margin from 31.6% to 30.1% quarter-on-quarter, though EBITDA margin was maintained at 11.7% through tight cost controls. The company took price hikes in four tranches (January through April) totaling ~8-9% to offset costs. Lead-acid business guidance for FY27 is high single-digit to early double-digit growth, with medium-term 5-year CAGR target of ~11%. Lithium-ion cell manufacturing is progressing: Rs. 4,802 crore invested in Exide Energy so far, with Rs. 1,400 crore planned for FY27, cylindrical samples starting this month and prismatic trials imminent. Total capacity of 6 GW (3 GW each cylindrical and prismatic) with 90% yield and import-parity pricing targets.

Likely market impact

Exide's core lead-acid business is performing well with strong volume growth offsetting commodity inflation through successful price hikes. The lithium-ion venture is progressing but meaningful revenue is still quarters away. Investors should monitor the margin impact from continued commodity volatility and the timeline for commercial cell supplies.